Thermo Fisher Scientific Exposure Increased
I last reviewed Thermo Fisher Scientific (TMO) in this August 2 post at which time Q2 and YTD2023 results had recently been released; I concluded shares were overvalued at ~$544. Following that post: TMO completed the CorEvitas acquisition I touched upon in my previous post. Novo Nordisk hired TMO to help fill the injection pens [...]